共 50 条
Outcomes following Kidney transplantation in IgA nephropathy: a UNOS/OPTN analysis
被引:8
|作者:
Kadiyala, Aditya
[1
,2
]
Mathew, Anna T.
[1
,2
]
Sachdeva, Mala
[1
,2
]
Sison, Cristina P.
[3
,4
,5
]
Shah, Hitesh H.
[1
,2
]
Fishbane, Steven
[1
,2
]
Jhaveri, Kenar D.
[1
,2
]
机构:
[1] N Shore Univ Hosp, Div Kidney Dis & Hypertens, Dept Med, Great Neck, NY USA
[2] Hofstra North Shore LIJ Sch Med, Long Isl Jewish Med Ctr, Great Neck, NY USA
[3] North Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Biostat Unit, Manhasset, NY USA
[4] Hofstra North Shore LIJ Sch Med, Dept Mol Med, Great Neck, NY USA
[5] Hofstra North Shore LIJ Sch Med, Dept Populat Hlth, Great Neck, NY USA
关键词:
epidemiology and outcomes;
glomerular disease;
IgA nephropathy;
transplantation;
IMMUNOGLOBULIN-A NEPHROPATHY;
RENAL-TRANSPLANTATION;
RECIPIENTS;
SURVIVAL;
D O I:
10.1111/ctr.12594
中图分类号:
R61 [外科手术学];
学科分类号:
摘要:
This study updates assessment of post-transplant outcomes in IgAN patients in the modern era of immunosuppression. Using UNOS/OPTN data, patients 18yr of age with first kidney transplant (1/1/1999 to 12/31/2008) were analyzed. Multivariable Cox regression models and propensity score-based matching techniques were used to estimate hazard ratios (HRs) for death-censored allograft survival (DCGS) and patient survival in IgAN compared to non-IgAN. Results of multivariable regression were stratified by donor type (living vs. deceased). A total of 107, 747 recipients were included (4589 with IgAN and 103158 with non-IgAN). Adjusted HR for DCGS showed no significant difference between IgAN and non-IgAN. IgAN had higher patient survival compared to non-IgAN (HR 0.54, 95% CI 0.47-0.62, p<0.0001 for deceased donors; HR 0.42, 95% CI 0.33-0.54, p<0.0001 for living donors). Propensity score-matched analysis was similar, with no significant difference in DCGS between matched groups and higher patient survival in IgAN patients compared to non-IgAN group (HR 0.54, 95% CI 0.47, 0.63; p-value <0.0001). IgAN patients with first kidney transplant have superior patient survival and similar graft survival compared to non-IgAN recipients. Results can be used in prognostication and informed decision-making about kidney transplantation in patients with IgAN.
引用
收藏
页码:911 / 919
页数:9
相关论文